Patents by Inventor Shuwen Liu

Shuwen Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210017189
    Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.
    Type: Application
    Filed: April 9, 2018
    Publication date: January 21, 2021
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Kui CHENG, Shuwen LIU, Gengzhen ZHU
  • Publication number: 20200390073
    Abstract: The present disclosure relates to genetically modified animals and cells with humanized heavy chain immunoglobulin locus and/or humanized light chain immunoglobulin locus.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 17, 2020
    Inventors: Yuelei Shen, Jiawei Yao, Huizhen ZHAO, Yabo ZHANG, Lili Liu, Hui LU, Shuwen HUANG
  • Publication number: 20200347419
    Abstract: A recombinant bacterium for producing L-lysine, a construction method thereof, and a method for producing L-lysine by using the recombinant bacterium. The recombinant bacterium has increased expression and/or activity of asparaginase compared to a starting bacterium.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 5, 2020
    Inventors: Tingyi WEN, Chen ZHANG, Xiuling SHANG, Xin CHAI, Yun ZHANG, Shuwen LIU, Guoqiang WANG, Zhongcai LI
  • Patent number: 10759757
    Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: September 1, 2020
    Assignees: Macau University of Science and Technology, Southern Medical University
    Inventors: Jinxiang Chen, Jianxin Pang, Shuwen Liu, Li-Ping Bai, Zhi-Hong Jiang
  • Publication number: 20200231606
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: August 24, 2017
    Publication date: July 23, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Abdelghani Achab, Purakkattle Biju, Timothy A. Cernak, Yongqi Deng, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Guoqing Li, Qinglin Pu, Zhi-Cai Shi, Wensheng Yu, Hongjun Zhang
  • Publication number: 20200208188
    Abstract: The invention relates to a plasmid, a DNA assembly method and its application recombinant strain. The plasmid has single adjacent Type IIP and Type IIS RE recognition sites. The plasmid combines the properties of Type IIP and Type IIS REs to achieve recursive cycling, SCAR-free and repeat sequence assembly.
    Type: Application
    Filed: December 23, 2019
    Publication date: July 2, 2020
    Inventors: Shuwen LIU, Tingyi WEN, Yun ZHANG, Aihua DENG
  • Publication number: 20200102278
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Yongxin Han, Kun Liu, Shuwen He, Joseph Kozlowski, Ravi Nargund, Wensheng Yu, Hongjun Zhang, Qinglin Pu, Derun Li, Abdelghani Achab, Guoqing Li
  • Publication number: 20200095212
    Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: February 19, 2018
    Publication date: March 26, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Dane Clausen, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Qinglin Pu, Wensheng Yu, Hongjun Zhang
  • Patent number: 10538497
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: January 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera, Liangqin Guo, Shuwen He, Joseph Kozlowski, Ravi Kurukulasuriya, Kun Liu, Meredeth Ann McGowan, Qinglin Pu, Nunzio Sciammetta, Hongjun Zhang, Hua Zhou
  • Publication number: 20190338282
    Abstract: The present invention discloses a method for modifying an amino acid attenuator, a class of amino acid attenuator mutants, engineered bacteria created on the basis of the amino acid attenuator mutants, and use of the engineered bacteria. The present invention protects a method for relieving the attenuation regulation of an amino acid operon gene, which is modification of the amino acid operon gene by: removing a gene coding for a leader peptide and an anterior reverse complementary palindromic sequence in the terminator stem-loop structure, and maintaining a posterior reverse complementary palindromic sequence in the terminator. The amino acid operon particularly can be histidine operon, tryptophan operon, phenylalanine operon, alanine operon, threonine operon and etc.
    Type: Application
    Filed: October 24, 2017
    Publication date: November 7, 2019
    Inventors: Tingyi Wen, Shuwen Liu, Yun Zhang, Xiuling Shang, Haihan Xiao
  • Publication number: 20190322995
    Abstract: A method for fermentation-production of a pentanediamine, comprising: culturing a cell expressing a lysine decarboxylase to obtain a whole cell fermentation broth comprising a pentanediamine; and extracting the pentanediamine from the whole cell fermentation broth, and striping the whole cell fermentation broth of carbon dioxide contained therein before adding a strong base. The method greatly increases a production volume of the pentanediamine.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 24, 2019
    Applicant: Ningxia EPPEN Biotech Co., Ltd
    Inventors: Jiyin MA, Tingyi WEN, Shuwen LIU, Yong LIANG, Daihuan LI, Yun ZHANG, Xiuling SHANG, Chunguang ZHAO, Xiaowei GUO, Gang MENG
  • Publication number: 20190155851
    Abstract: This application discloses an information filtering method and an information processing apparatus. Shared information that is shared by a user account of an online service is obtained. A credibility reference rating associated with the user account is obtained. The credibility reference rating indicates account credibility of the user account. Whether the shared information satisfies a filtering condition is determined based on the credibility reference rating. Further, the shared information is filtered when the shared information is determined to satisfy the filtering condition.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 23, 2019
    Applicant: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Xingya WANG, Qian Chen, Boen Liang, Jinzheng Zhang, Jianwei Yuan, Leming Fang, Chao Wan, Jilan Liang, Zijian He, Rui Tang, Zhike Liang, Xin Huang, Huankun Huang, Haixia Rao, Junwei Shen, Jun Zhang, Shuqin Sun, Pengfei Wang, Yingchao Liu, Wa Ye, Fei Huang, Jiasheng Huang, Zheqi Feng, Luting Chen, Shuwen Hu, Lingyun Xu
  • Patent number: 10017798
    Abstract: The present invention discloses an E. coli engineering bacteria producing 1,5pentanediamine through a whole cell catalysis and its application. The engineering bacteria according to the present invention, is Escherichia coli (E. coli) strain B or its derivative strains with the overexpression of a lysine decarboxylase gene and a proper expression of a lysinecadaverine antiporter gene cadB.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: July 10, 2018
    Assignee: NINGXIA EPPEN BIOTECH CO., LTD
    Inventors: Tingyi Wen, Shuwen Liu, Yong Liang, Xiuling Shang, Qian Liu, Jifu Wen, Yun Zhang
  • Publication number: 20180078660
    Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 22, 2018
    Inventors: Jinxiang Chen, Jianxin Pang, Shuwen Liu, Li-Ping Bai, Zhi-Hong Jiang
  • Patent number: 9796991
    Abstract: The present invention relates to recombinant bacteria producing L-amino acid, in which the recombinant bacteria has reduced expression of the glucose-6-phosphate isomerase gene pgi and improved expression of the glucose-6-phosphate dehydrogenase gene -opcA than the starting bacteria, where the starting bacterium is a bacterial strain that can accumulate target amino acid(s) and preferably, the amino acid is L-histidine.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: October 24, 2017
    Assignee: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Tingyi Wen, Xiuling Shang, Yun Zhang, Shuwen Liu, Yong Liang, Yu Zhang
  • Publication number: 20170226544
    Abstract: The present invention discloses an E. coli engineering bacteria producing 1,5-pentanediamine through a whole cell catalysis and its application. The engineering bacteria according to the present invention, is Escherichia coli (E. coli) strain B or its derivative strains with the overexpression of a lysine decarboxylase gene and a proper expression of a lysine-cadaverine antiporter gene cadB. The engineering bacteria according to the present invention is the engineering bacteria producing 1,5-pentanediamine through the whole cell catalysis constructed from Escherichia coli B derivative strains, which has an overexpression of a lysine decarboxylase gene cadA and a proper expression of the lysine-cadaverine antiporter gene cadB.
    Type: Application
    Filed: June 25, 2015
    Publication date: August 10, 2017
    Inventors: TINGYI WEN, SHUWEN LIU, YONG LIANG, XIULING SHANG, QIAN LIU, JIFU WEN, YUN ZHANG
  • Publication number: 20160326556
    Abstract: The present application discloses recombinant bacteria producing L-amino acid(s) its construction method and the method of producing L-amino acid(s). The recombinant bacteria producing L-amino acid(s) according to the present invention has reduced expression of the glucose-6-phosphate isomerase Pgi and improved expression of the glucose-6-phosphate dehydrogenase Zwf-OpcA than the starting bacteria, wherein: said starting bacterium is a bacterial strain which can accumulate target amino acid(s). During fermenting and culturing the recombinant bacteria according to the present invention, it is observed that the effect of improving yield can be additive and the yield of L-amino acid(s) is improved obviously. The strategy of combinational modification according to the present invention develops a new method of improving the yield of L-amino acid(s) and hence it can be applied to produce L-amino acid(s) through bacterialfermentation.
    Type: Application
    Filed: February 4, 2015
    Publication date: November 10, 2016
    Applicant: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Tingyi Wen, Xiuling Shang, Yun Zhang, Shuwen Liu, Yong Liang, Yu Zhang
  • Publication number: 20160002684
    Abstract: A method for producing L-lysine by fermentation comprises the steps of modifying an aconitase gene and/or regulatory element thereof in a chromosome of a bacterium so that the activity and/or the expression amount of the aconitase of the bacterium are reduced but not eliminated; and producing L-lysine by the fermentation of the modified bacterium. In addition, also provided are methods and uses derived from the method as well as bacteria used in these methods and uses.
    Type: Application
    Filed: January 7, 2014
    Publication date: January 7, 2016
    Inventors: Jiyin MA, Tingyi WEN, Jinlong CHEN, Yong LIANG, Shuwen LIU, Aiying WEI, Lipeng YANG, Rui REN, Gang MENG, Chunguang ZHAO, Yun ZHANG, Xiuling SHANG, Xiaowei GUO
  • Patent number: 8906927
    Abstract: The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R1 is selected from a group consisting of linear or branched alkyls and substituted alkyls. R2 and R4 is respectively selected from a group consisting of linear or branched alkyls, substituted alkyls, cycloalkyls, substituted cycloalkyls, aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, heterocyclyls, substituted heterocyclyls, aromatic heterocyclyls and substituted aromatic heterocyclyls. R3 is selected from a group consisting of aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, aromatic heterocyclyls and substituted aromatic heterocyclyls. The penta-substituted tetrahydropyrimidines can be prepared by multi-component reactions (MCR).
    Type: Grant
    Filed: December 24, 2011
    Date of Patent: December 9, 2014
    Assignee: Southern Medical University
    Inventors: Qiuhua Zhu, Shuwen Liu
  • Publication number: 20140051855
    Abstract: The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R1 is selected from a group consisting of linear or branched alkyls and substituted alkyls. R2 and R4 is respectively selected from a group consisting of linear or branched alkyls, substituted alkyls, cycloalkyls, substituted cycloalkyls, aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, heterocyclyls, substituted heterocyclyls, aromatic heterocyclyls and substituted aromatic heterocyclyls. R3 is selected from a group consisting of aryls, substituted aryls, polycyclic aryls, substituted polycyclic aryls, aromatic heterocyclyls and substituted aromatic heterocyclyls. The penta-substituted tetrahydropyrimidines can be prepared by multi-component reactions (MCR).
    Type: Application
    Filed: December 24, 2011
    Publication date: February 20, 2014
    Applicant: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Qiuhua Zhu, Shuwen Liu